Trials / Completed
CompletedNCT00219583
Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation
A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 460 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of efficacy and safety UK-390,957.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UK-390,957 |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2005-06-01
- Completion
- 2005-06-01
- First posted
- 2005-09-22
- Last updated
- 2012-11-07
Locations
49 sites across 14 countries: Australia, Austria, Canada, Czechia, France, Germany, Israel, Italy, Netherlands, Norway, Poland, Spain, Sweden, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00219583. Inclusion in this directory is not an endorsement.